A 52-Week Multi-Center Randomized Double-Blind Placebo-Controlled Parallel Group Study with Mild Alzheimer
M
Martin Farlow, MD
Primary Investigator
Overview
No Description Available
Description
No Description Available
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Alzheimer's Disease
-
Age: Between 40 Years - 85 Years
-
Gender: All
Updated on
24 Apr 2024.
Study ID: 0806-05
